B
Barbara Roniker
Researcher at Pharmacia
Publications - 36
Citations - 7286
Barbara Roniker is an academic researcher from Pharmacia. The author has contributed to research in topics: Eplerenone & Aldosterone. The author has an hindex of 17, co-authored 36 publications receiving 6973 citations. Previous affiliations of Barbara Roniker include National Cheng Kung University & Pfizer.
Papers
More filters
Journal ArticleDOI
Efficacy of Eplerenone Added to Renin-Angiotensin Blockade in Hypertensive Patients
Henry Krum,Hector Nolly,Diane Workman,Weizhong He,Barbara Roniker,Scott Krause,Kaffa Fakouhi +6 more
TL;DR: It is demonstrated that in patients whose blood pressure was not controlled with an ACE inhibitor or ARB, the addition of eplerenone over an 8-week period significantly lowered systolic BP in both groups and diastolicBP in ARB patients.
Journal ArticleDOI
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients
John M. Flack,Suzanne Oparil,J. Howard Pratt,Barbara Roniker,Susan M. Garthwaite,Jay H. Kleiman,Yonghong Yang,Scott Krause,Diane Workman,Elijah Saunders +9 more
TL;DR: Eplerenone was as effective in reducing SBP and DBP in the high renin patient, but more effective than losartan in the low renin patients, and was superior to placebo in white patients.
Journal ArticleDOI
Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension
Gordon H. Williams,Ellen Burgess,R. Kolloch,Luis M. Ruilope,Joanna Niegowska,Mark S Kipnes,Barbara Roniker,Jeffrey L. Patrick,Scott Krause +8 more
TL;DR: Eplerenone was as effective as enalapril as monotherapy in patients with stage 1 or 2 hypertension, was more effective in reducing albuminuria, and was well tolerated for 12 months.
Journal ArticleDOI
OR-54: Antiproteinuric efficacy of eplerenone, enalapril, and eplerenone/enalapril combination therapy in diabetic hypertensives with microalbuminuria
Murray Epstein,V. Buckalew,F. Martinez,J. Altamirano,Barbara Roniker,Jay H. Kleiman,Scott Krause +6 more
Journal ArticleDOI
Eplerenone: A Selective Aldosterone Receptor Antagonist (SARA)
John A. Delyani,Ricardo Rocha,Chyung S. Cook,Dwain S. Tolbert,Stuart Levin,Barbara Roniker,Diane Workman,Yuen-lung L. Sing,Brian Whelihan +8 more
TL;DR: In rodent models, eplerenone provides marked protection against vascular injury in the kidney and heart and is well tolerated in acute and chronic safety pharmacology studies, which will extend the understanding of selective aldosterone receptor antagonism in the treatment of chronic cardiovascular disease.